CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...